Back to search results

Exploring the ELF Test for Early Fatty Liver Detection

This study is looking back at information from patients at Methodist Dallas Medical Center to see how well a blood test called the Enhanced Liver Fibrosis (ELF) score can find early signs of fatty liver disease. This is important for people at high risk, such as those with metabolic syndrome (a group of conditions that increase your risk of heart disease, stroke, and type 2 diabetes). The study aims to compare the ELF test to older methods of checking for liver scarring (fibrosis), like FibroScan or liver biopsy, which can be more expensive or invasive. By using existing patient data, researchers hope to learn if the ELF test is a good, easy-to-use option for doctors to detect liver problems sooner.

Study design
This is an observational study looking at existing patient data. It plans to include 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study looks at patient information, including ELF scores, hospital admissions, and demographics, at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06225193

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

Recruiting
Not specifiedAges 18+Observational
Methodist Health System
~300 participants
Updated 2026-05-13 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Enhanced Liver Fibrosis (ELF )scores
Measured over 6 months
+3 more outcomes measured

Conditions

Fatty Liver

Explore related trials

Fatty liverELF score

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Parvez Mantry, MD · PRINCIPAL_INVESTIGATOR · Methodist Midlothian Medical Center

Who to contact

Crystee Cooper
[email protected]
2149471280
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age: ≥ 18 years
NAFLD/NASH and non-NAFLD/NASH patients who have had an assessment with ELF score at Methodist Dallas Medical Center from November 2021 to December 2023.

Exclusion

Patients with incomplete data and those lost to follow up.

What this trial measures

  • Enhanced Liver Fibrosis (ELF )scores6 months

    Will measure the ELF scores-Reference range 7.14-9.55, the lowest value means better and highest value would mean worst

  • Instances of hospital admission for ascites, edema/anasarca, portal hypertensive-related bleeding or encephalopathy6 months

    Number of hospital admissions for ascites, edema/anasarca, portal hypertensive-related bleeding or encephalopathy

  • Demographics6 months

    age (years), gender (male/female), race (Caucasian, Black, Hispanic, Asian, Other)

  • Instances of comorbidities6 months

    Patients with hypertension(HTN), Hypersensitivity Lung Disease(HLD), Coronary Artery Disease(CAD),Heart Failure( HF), Atherosclerotic cardiovascular disease (ASCVD), Type 2 Diabetes Mellitus(T2DM) as comorbidities